Analyst Research: Gilead Sciences Inc (GILD.O)
GILD.O on Nasdaq
50.60USD
19 Jun 2013
50.60USD
19 Jun 2013
Price Change (% chg)
$-1.34 (-2.58%)
$-1.34 (-2.58%)
Prev Close
$51.94
$51.94
Open
$51.82
$51.82
Day's High
$52.05
$52.05
Day's Low
$50.57
$50.57
Volume
6,408,557
6,408,557
Avg. Vol
12,219,417
12,219,417
52-wk High
$58.06
$58.06
52-wk Low
$24.80
$24.80
| Name | Age | Since | Current Position |
|---|---|---|---|
John Martin |
61 | 2008 | Chairman of the Board, Chief Executive Officer |
John Milligan |
52 | 2008 | President, Chief Operating Officer |
Robin Washington |
50 | 2008 | Chief Financial Officer, Senior Vice President |
Norbert Bischofberger |
57 | 2007 | Executive Vice President - Research and Development, Chief Scientific Officer |
Gregg Alton |
47 | 2009 | Executive Vice President - Corporate and Medical Affairs |
- FDA grants priority review status to Gilead's hepatitis C drug
- Experimental Gilead drug effective in early-stage leukemia trial
- Experimental Gilead drug effective in early-stage leukemia trial
- Gilead profit rises, but sales of older HIV drugs dip
- UPDATE 2-Gilead profit rises, but sales of older HIV drugs dip

